In addition, the CROWN trial randomized 296 treatment-naïve patients with ALK-mutated NSCLC to lorlatinib or crizotinib, and a post hoc analysis demonstrated that in the patients with baseline BrMs (n = 37 lorlatinib, n = 39 crizotinib), the intracranial ORR was 65% vs. 18% favoring lorlatinib [81]. This evidence concerns the gene ALK and non-small cell lung carcinoma.